Variants of IRF1, IFNAR2 and DR1 associated with lower COVID-19 severity increase type I IFN signalling in lymphoid cells by upregulating IRF1 and IFNAR2 or downregulating DR1, attesting to the importance of efficient IFN signalling for a favourable clinical outcome4,12–14. This evidence concerns the gene IFNAR2 and COVID-19.